← Back to Search

NMDA Receptor Antagonist

Ketamine for Obsessive-Compulsive Disorder(MKET Trial)

Stanford University, Stanford, CA
Ketamine +1 morePhase 2Waitlist AvailableLed by Carolyn I Rodriguez, MD, PhDResearch Sponsored by Stanford University

MKET Trial Summary

This trial will test how well ketamine works to reduce OCD symptoms compared to a placebo.

MKET Trial Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
Select...
You have a primary diagnosis of OCD.
Select...
Your OCD symptoms need to be severe enough to qualify for the study.
Select...
You are between 18 and 65 years old.
Select...
You are between the ages of 18 and 65.
Select...
You should be able to take a break from any current treatments.

MKET Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)
Secondary outcome measures
Regional gamma-aminobutyric acid, glutamate/glutamine levels derived from 3T Magnetic Resonance Spectroscopy

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

MKET Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: KetamineExperimental Treatment1 Intervention
OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
Group II: MidazolamActive Control1 Intervention
OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine
2011
Completed Phase 4
~1090

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,324 Previous Clinical Trials
17,287,838 Total Patients Enrolled
13 Trials studying Obsessive-Compulsive Disorder
1,296 Patients Enrolled for Obsessive-Compulsive Disorder
University of ConnecticutOTHER
175 Previous Clinical Trials
157,525 Total Patients Enrolled
Carolyn I Rodriguez, MD, PhDPrincipal InvestigatorStanford University
3 Previous Clinical Trials
41 Total Patients Enrolled
1 Trials studying Obsessive-Compulsive Disorder
7 Patients Enrolled for Obsessive-Compulsive Disorder

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what ailments is Ketamine typically applied?

"Ketamine is a well-known treatment for seizures and epilepsy, but it can also ameliorate the symptoms of amnesia and be employed in certain therapeutic processes."

Answered by AI

Are any openings currently available for the trial's participants?

"Unfortunately, no longer are individuals being accepted for this trial. The posting date of June 1st 2016 and last update on May 24th 2022 indicate that recruitment has ceased; however, there are currently 114 active clinical trials involving patients with obsessive-compulsive disorder and 153 studies actively recruiting participants to test Ketamine's efficacy."

Answered by AI

How many patients have been enrolled for participation in this experiment?

"Currently, this study is not accepting patients. Initially posted on June 1st 2016 and final edited May 24th 2022, no further submissions are being accepted at the moment. However, there are 114 medical studies recruiting for all individuals with obsessive-compulsive disorder and another 153 clinical trials searching for suitable candidates to test Ketamine's efficacy."

Answered by AI

Is there an age limit for enrollees in this investigation?

"The age restrictions for participation in this clinical trial are clear. Participants must be above the legal age of consent and not exceed 65 years old."

Answered by AI

Is Ketamine associated with any hazardous effects?

"Ketamine's safety has been established to some degree, so it is given a score of 2. Despite this, there is no evidence that the drug can be effective in treating any conditions yet."

Answered by AI

To whom is participation in this trial available?

"In order to be accepted into this clinical trial, candidates must present with obsessive-compulsive disorder and lie within the age range of 18 - 65. The study is currently seeking 120 participants."

Answered by AI

Who else is applying?

What state do they live in?
Manitoba
California
Washington
Other
How old are they?
18 - 65
What site did they apply to?
Stanford University
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

How responsive is this trial?

Typically responds via
Email
Most responsive sites:
  1. Stanford University: < 24 hours
Average response time
  • < 1 Day
Recent research and studies
Harvard Review of PsychiatryJournal
Ketamine in the Treatment of Obsessive-compulsive Disorder: A Systematic Review
Bandeira, Igor D., Daniel H. Lins-Silva, Vitor Breseghello Cavenaghi, Ingrid Dorea-Bandeira, Daniela Faria-Guimarães, Judah L. Barouh, Ana Paula Jesus-Nunes, et al.. 2022. “Ketamine in the Treatment of Obsessive-compulsive Disorder: A Systematic Review”. Harvard Review of Psychiatry. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/hrp.0000000000000330.
clinicaltrials.govStudy
Understanding How Ketamine Brings About Rapid Improvement in OCD
Carolyn Rodriguez 2016. "Understanding How Ketamine Brings About Rapid Improvement in OCD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02624596.
All > Obsessive Compulsive Disorder > Ocd
~6 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top